ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
AVBP Stock Chart & Stats
$22.75
$0.14(0.52%)
At close: 4:00 PM EST
$22.75
$0.14(0.52%)
Day’s Range― - ―
52-Week Range$15.47 - $27.22
Previous CloseN/A
Volume49.09K
Average Volume (3M)516.87K
Market Cap
$963.82M
Enterprise Value$918.29M
Total Cash (Recent Filing)$312.82M
Total Debt (Recent Filing)$14.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 13, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding44,201,622
10 Day Avg. Volume471,604
30 Day Avg. Volume516,866
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.34
Forecast
1Y Price Target
$43.22Price Target Upside89.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline OptionalityAdvancement of the antibody-drug conjugate program, including a CDH17-directed candidate entering early clinical testing, provides development optionality that could generate additional commercial upside beyond the lead program.
Product DifferentiationFirmonertinib's oral, chemotherapy-free, brain-penetrant profile could offer improved tolerability and superior intracranial activity compared with intravenous chemo-containing regimens, supporting potential clinical adoption in patients with brain metastases.
Regulatory And Commercialization PlanningRegulatory recognition through Breakthrough Therapy designation and visible preparations for potential approval signal readiness for market access that could accelerate commercialization if pivotal data are favorable.
Bears Say
Competition And Data LimitationsA competitive landscape that includes therapies like Rybrevant, coupled with a limited Phase 2 dataset lacking prior-treatment details for some mutations, could constrain market uptake and complicate regulatory or payer comparisons.
Financing And Dilution RiskLimited cash resources may necessitate additional financing before potential approvals, creating dilution for existing shareholders and added execution pressure.
Trial Readout RiskPostponement of the pivotal trial readout increases outcome uncertainty and raises the risk that the control arm could outperform expectations, which would materially weaken the investment case.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $15.47 and its highest was $27.22 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $963.82M.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is May 13, 2026 which is in 46 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Mar 05, 2026. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.846 by $0.006.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.9.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 44,201,622 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.846. Following the earnings report the stock price went down -7.208%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.22 (89.98% Upside)
$43.22 (89.98% Upside)
Blogger Sentiment
Bullish
AVBP Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 151.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.79%
12-Months-Change
Fundamentals
Return on Equity
-62.48%
Trailing 12-Months
Asset Growth
21.18%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$43.22
▲(89.98% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
Currently, No data available
---